Orlistato Ratiopharm (Orlistat)

Orlistat is indicated for the treatment of obesity and related metabolic conditions.

• Obesity: Reduces body weight when combined with a reduced‑calorie diet.
• Overweight with risk factors: Assists in weight loss for patients with a BMI ≥ 27 kg/m² who have comorbidities such as hypertension or dyslipidaemia.
• Weight‑maintenance: Helps maintain weight loss achieved through diet and lifestyle changes.
• Post‑bariatric surgery: Supports continued weight management after surgical weight‑loss procedures.
• Metabolic syndrome: Contributes to improvement of lipid profiles when used as part of a comprehensive management plan.

• Orlistat acts as a reversible inhibitor of gastric and pancreatic lipases. By binding to the active site of these enzymes, it prevents the hydrolysis of dietary triglycerides into absorbable free fatty acids, thereby reducing the amount of fat absorbed from the gastrointestinal tract and lowering caloric intake.

Adverse reactions to Orlistat are primarily related to its mechanism of reducing fat absorption.

Common Side Effects

• Oily spotting: Appearance of oily droplets on underwear or clothing.
• Fecal urgency: Increased frequency of bowel movements.
• Flatulence with discharge: Gas accompanied by oily discharge.
• Abdominal cramping: Discomfort or pain in the abdominal region.
• Loose stools: Frequent, watery stools.
• Reduced absorption of fat‑soluble vitamins: Lowered levels of vitamins A, D, E and K.

Serious or Rare Side Effects

• Liver injury: Signs of hepatitis or abnormal liver function tests.
• Severe allergic reaction: Rash, itching, swelling, dizziness or trouble breathing.
• Pancreatitis: Sudden, severe abdominal pain radiating to the back.
• Kidney stones: Flank pain, hematuria or urinary obstruction.
• Persistent diarrhea: Ongoing watery stools leading to dehydration.
• Acute colitis: Inflammation of the colon presenting with blood in stool.

When using Orlistat, certain precautions should be observed to ensure safety and effectiveness.

• Assess BMI: Confirm that the patient meets the BMI criteria for treatment.
• Monitor vitamin levels: Supplement fat‑soluble vitamins regularly to prevent deficiencies.
• Review medical history: Check for history of malabsorption, cholestasis or pancreatitis.
• Counsel on diet: Advise a low‑fat diet to minimise gastrointestinal side effects.
• Evaluate liver function: Periodic liver enzyme testing is recommended.
• Store at ambient temperature: Keep below 25°C in the original packaging, protected from moisture.

Orlistat can interact with several medicines and nutrients, affecting their absorption or efficacy.

Major Interactions (Avoid)

• Cyclosporine: Reduced absorption may lower immunosuppressive effect.
• Levothyroxine: Decreased uptake can compromise thyroid hormone replacement.
• Warfarin: Altered vitamin K absorption may affect anticoagulation control.

Moderate Interactions (Monitor Closely)

• Fat‑soluble vitamins (A, D, E, K): Co‑administration requires supplementation.
• Beta‑blockers: Possible reduction in drug plasma levels.
• Antiretrovirals (e.g., ritonavir): May experience reduced efficacy due to decreased fat absorption.